Guyana vs Philippines: Statin use vs. average non-HDL cholesterol levels
Guyana
3.9
in 2018
Philippines
4
in 2018
Guyana rank
4th
Philippines rank
2nd
Statin use vs. average non-HDL cholesterol levels over time
- Guyana
- Philippines
How they compare
Philippines currently reports 4 against 3.9 in Guyana, a difference of 0.1.
Across all 39 years both countries report, Philippines has been ahead every year.
Guyana ranks 4th and Philippines ranks 2nd of 191 countries.
Philippines has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Guyana | Philippines | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.36 | 3.45 | 0.09 | Philippines |
| 1990s | 3.3 | 3.51 | 0.21 | Philippines |
| 2000s | 3.46 | 3.65 | 0.19 | Philippines |
| 2010s | 3.74 | 3.9 | 0.1556 | Philippines |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Guyana or Philippines?
- Philippines, at 4 against 3.9 in Guyana as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Guyana and Philippines?
- 0.1, with Philippines ahead.
- How many years of comparable data are there for Guyana and Philippines?
- 39 years are reported by both, from 1980 to 2018.
- How do Guyana and Philippines rank globally for statin use vs. average non-hdl cholesterol levels?
- Guyana ranks 4th and Philippines ranks 2nd of 191 countries.
- Where does this data come from?
- World Health Organization – Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.